Addressing Hepatitis C in the American Incarcerated Population: Strategies for Nationwide Elimination
| Autor: | Selin Ocal, Andrew J. Muir |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Burden of disease Liver Cirrhosis Male Cost-Benefit Analysis Population Disease Hepacivirus Antiviral Agents 03 medical and health sciences 0302 clinical medicine Virology Environmental health Prevalence Medicine Humans Mass Screening 030212 general & internal medicine education education.field_of_study Prison population business.industry Prisoners social sciences Hepatitis C Hepatitis C Chronic medicine.disease Hcv elimination United States 030104 developmental biology Infectious Diseases Medicine public health Female business |
| Zdroj: | Current HIV/AIDS reports. 17(1) |
| ISSN: | 1548-3576 |
| Popis: | The prevalence of Hepatitis C virus (HCV) in the US incarcerated population is disproportionately high, and when inmates with infection are released back into the general population, they play a substantial role in the spread of disease. This review provides support for targeting the jail/prison population to eliminate HCV in the general population. It will also summarize various screening/treatment models to curtail the burden of disease behind and beyond bars. Transitioning from risk-based testing to opt-out testing in prisons/jails would be cost-effective through greater identification of cases and treatment to prevent complications from cirrhosis. Other innovative strategies, such as the nominal pricing mechanism or the “Netflix” DAA subscription model, have the potential to be cost-effective and to increase access to treatment. Addressing HCV in the incarcerated population is a strategy to bring the US closer to successfully eradicating the epidemic. Such findings should incentivize policymakers to implement care models that target this population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink